Additional file 1 of Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Abstract

Additional file 1: Supplementary Figure 1. The selecting procedure of studying cohorts. Supplementary Figure 2. Prognostic significance of VISTA+ TCs infiltration in MIBC patients. Supplementary Figure 3. Identification of immune cells and checkpoints based on VISTA+ ICs infiltration in ZSHS Cohort. Supplementary Figure 4. Somatic alterations in signaling pathways across VISTA+ ICs infiltration. Supplementary Table 1. Clinicopathological characteristics and relationship with VISTA+ cells infiltration in ZSHS cohort. Supplementary Table 2. Clinicopathological characteristics and relationship with VISTA+ ICs infiltration in TCGA cohort. Supplementary Table 3. Clinicopathological characteristics and relationship with VISTA+ ICs infiltration in IMvigor210 cohort. Supplementary Table 4. Immunohistochemistry antibodies and quantification. Supplementary Table 5. Specific gene signatures. Supplementary Table 6. Univariate analysis of clinicopathologic features and VISTA+ ICs/ VISTA+ TCs infiltration in ZSHS Cohort. Supplementary Table 7. Univariate analysis of clinicopathologic features and VISTA+ ICs signature infiltration in TCGA Cohort. Supplementary Table 8. Multivariate analysis of clinicopathologic features and VISTA+ TCs infiltration in ZSHS Cohort